- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- Selected as a pilot for the Whole Lifecycle Assessment (WLA) approach.
- Process:
- MTA Standard
- ID number:
- 6689
Provisional Schedule
- Committee meeting:
- 09 February 2027
- Expected publication:
- 10 June 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Amgen (denosumab)
- Aspire Pharma (ibandronic acid, raloxifene, risedronate sodium)
- Atnahs Pharma (ibandronic acid)
- Aurobindo Pharma - Milpharm (alendronic acid, risedronate sodium)
- Bowmed Ibisqus (zoledronic acid)
- Celltrion Healthcare UK (denosumab)
- Dr. Reddy's Laboratories (denosumab, zoledronic acid)
- Eli Lilly (teriparatide)
- Ennogen IP (zoledronic acid)
- Fresenius Karbi (denosumab, zoledronic acid)
- Gedeon Richter (denosumab, teriparatide)
- Genus Pharmaceuticals (denosumab)
- Internis Pharmaceuticals (alendronic acid)
- Mabxience Research (denosumab)
- Martindale Pharma, an Ethypharm Group Company (zoledronic acid)
- Morningside Healthcare (zoledronic acid)
- Organon Pharma (alendronic acid, denosumab)
- Pheonix Labs (zoledronic acid)
- Rosemont (alendronic acid)
- Samsung Bioepis UK (denosumab)
- Sandoz (alendronic acid, denosumab, ibandronic acid, risedronate sodium, zoledronic acid)
- Seacross Pharmaceuticals (zoledronic acid)
- Sovereign Medical (risedronate sodium)
- Sun Pharmaceutical Company (teriparatide, zoledronic acid)
- Teva UK (denosumab, teriparatide)
- Theramex (abaloparatide)
- Tillomed Laboratories (zoledronic acid)
- Thornton & Ross (teriparatide)
- UCB Pharma (romosozumab)
- Unicorn Pharmaceuticals (zoledronic acid)
- Viatris (alendronic acid, zoledronic acid)
- Zentiva (denosumab)
- Others
- Department of Health and Social Care
- Health Technology Wales (HTW)
- NHS England
- Patient carer groups
- Action on Pain
- Arthritis Action
- Arthritis UK
- Arthritis & Musculoskeletal Alliance
- BackCare
- BAME Health Collaborative Charity
- Black Health Agency for Equality
- Daisy Network
- Menopause Charity
- Menopause Exchange
- Menopause Matters
- Menopause UK
- Pain Concern
- Pain UK
- Pregnancy Associated osteoporosis UK
- Queermenopause
- Royal Osteoporosis Society
- South Asian Health Foundation
- Specialised Healthcare Alliance
- The Pain Relief Foundation
- Women’s Health Concern
- Professional groups
- British Dietetic Association
- British Geriatrics Society
- British Institute of Radiology
- British Menopause Society
- British Orthopaedic Association
- British Pain Society
- British Society of Rehabilitation Medicine
- British Society for Rheumatology
- National Osteoporosis Guideline Group
- Physiotherapy Pain Association
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and the College of
- Radiographers
- Society for Endocrinology
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Bone Research Society
- Chronic Pain Policy Coalition
- Cochrane Bone, Joint and Muscle Trauma Group
- Cochrane Gynaecology and Fertility Group
- Cochrane Metabolic & Endocrine Disorders Group
- Cochrane Musculoskeletal Group
- Cochrane UK
- Genomics England
- MRC Clinical Trials Unit
- National Institute of Health and Care Research
Related links
- Consultation on draft scope and guideline update
- Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 June 2026 | Invitation to participate |
| 13 January 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 13 January 2026 | Note - Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual